Last reviewed 2026-04-23 · How we verify

A. CNS 7056

CNS 7056 is a kappa opioid receptor antagonist.

CNS 7056 is a kappa opioid receptor antagonist. Used for Treatment of acute pain.

At a glance

Mechanism of action

CNS 7056 works by blocking the kappa opioid receptor, which is involved in pain modulation and other physiological processes. This action is thought to contribute to its analgesic effects.

Approved indications

• Treatment of acute pain

Common side effects

• Nausea
• Vomiting
• Dizziness

Key clinical trials

• Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
• Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (PHASE2)
• Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy (NA)
• ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
• A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy (PHASE4)
• Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration (PHASE3)
• Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
• Remimazolam TIVA-Flumazenil Antagonism in Short-duration ENT Surgeries

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• A. CNS 7056 CI brief — competitive landscape report
• A. CNS 7056 updates RSS · CI watch RSS
• Paion UK Ltd. portfolio CI